Cy4gate Valuation

Is CY4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CY4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CY4 (€3.92) is trading below our estimate of fair value (€5.35)

Significantly Below Fair Value: CY4 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CY4?

Key metric: As CY4 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CY4. This is calculated by dividing CY4's market cap by their current revenue.
What is CY4's PS Ratio?
PS Ratio1.3x
Sales€67.59m
Market Cap€90.87m

Price to Sales Ratio vs Peers

How does CY4's PS Ratio compare to its peers?

The above table shows the PS ratio for CY4 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.9x
VNT Vantea SMART
1.1x-1.3%€14.7m
RLT Relatech
1.1x5.8%€108.3m
AIW Almawave
1.6x11.3%€84.6m
CYB Cyberoo
3.7x17.3%€85.3m
CY4 Cy4gate
1.3x13.7%€90.9m

Price-To-Sales vs Peers: CY4 is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (1.9x).


Price to Sales Ratio vs Industry

How does CY4's PS Ratio compare vs other companies in the European Software Industry?

42 CompaniesPrice / SalesEstimated GrowthMarket Cap
CY4 1.3xIndustry Avg. 2.0xNo. of Companies50PS0246810+
42 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CY4 is good value based on its Price-To-Sales Ratio (1.3x) compared to the European Software industry average (2x).


Price to Sales Ratio vs Fair Ratio

What is CY4's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CY4 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: CY4 is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CY4 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.92
€6.80
+73.7%
2.9%€7.00€6.60n/a2
Nov ’25€4.17
€7.65
+83.7%
13.7%€8.70€6.60n/a2
Oct ’25€4.97
€7.65
+54.1%
13.7%€8.70€6.60n/a2
Sep ’25€6.04
€8.85
+46.5%
1.7%€9.00€8.70n/a2
Aug ’25€6.20
€8.85
+42.7%
1.7%€9.00€8.70n/a2
Jul ’25€5.71
€8.85
+55.0%
1.7%€9.00€8.70n/a2
Jun ’25€6.54
€8.85
+35.3%
1.7%€9.00€8.70n/a2
May ’25€6.31
€8.85
+40.3%
1.7%€9.00€8.70n/a2
Apr ’25€5.77
€8.85
+53.4%
1.7%€9.00€8.70n/a2
Mar ’25€5.50
€9.75
+77.3%
7.7%€10.50€9.00n/a2
Feb ’25€7.46
€11.40
+52.8%
5.3%€12.00€10.80n/a2
Jan ’25€8.18
€11.40
+39.4%
5.3%€12.00€10.80n/a2
Dec ’24€7.99
€11.40
+42.7%
5.3%€12.00€10.80n/a2
Nov ’24€7.17
€11.80
+64.6%
8.5%€12.80€10.80€4.172
Oct ’24€7.34
€11.80
+60.8%
8.5%€12.80€10.80€4.972
Sep ’24€8.50
€12.35
+45.3%
6.9%€13.20€11.50€6.042
Aug ’24€8.01
€12.35
+54.2%
6.9%€13.20€11.50€6.202
Jul ’24€8.78
€12.85
+46.4%
10.5%€14.20€11.50€5.712
Jun ’24€8.80
€12.85
+46.0%
10.5%€14.20€11.50€6.542
May ’24€8.69
€12.85
+47.9%
10.5%€14.20€11.50€6.312
Apr ’24€9.80
€12.85
+31.1%
10.5%€14.20€11.50€5.772
Mar ’24€10.00
€13.60
+36.0%
11.8%€15.20€12.00€5.502
Feb ’24€9.24
€13.60
+47.2%
11.8%€15.20€12.00€7.462
Jan ’24€9.22
€14.00
+51.8%
14.3%€16.00€12.00€8.182
Dec ’23€9.70
€14.00
+44.3%
14.3%€16.00€12.00€7.992
Nov ’23€9.14
€14.00
+53.2%
14.3%€16.00€12.00€7.172

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies